Skip to content Skip to footer
Post 23

Vivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update

Part of the Vivos System Treatment, the mmRNA Device Represents a Highly Effective Non-Surgical, Non-Invasive and Non-Pharmaceutical Alternative for Patients Suffering from OSA. Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH Colorado, August 12, 2021 Vivos Therapeutics, Inc. (the…

Read More

Post 22

Vivos Therapeutics to Participate at the Q3 Virtual Investor Summit

Vivos management to present at 9:30 am Eastern Time on August 18, 2021 HIGHLANDS RANCH   Colorado, August 9, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk…

Read More

Post 21

Vivos Therapeutics Schedules Second Quarter 2021 Financial Results Conference Call

Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET HIGHLANDS RANCH   Colorado, August 9, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it…

Read More

Post 20

Vivos Therapeutics Opens State of the Art International Training Center In Denver

The Vivos Institute Is Expected to Significantly Increase Vivos’ Ability to Educate Healthcare Providers on Ways to Help Millions of People Suffering from Sleep Apnea and its Comorbidities HIGHLANDS RANCH   Colorado, July 29, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and…

Read More

Post 19

One in Four Patients in Latest Clinical Study Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment

HIGHLANDS RANCH   Colorado, July 13, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced results from a national study commissioned by the Company to assess patients’…

Read More

Post 18

Independent Study Shows 97 Percent of Vivos Patients Achieved Their Desired Treatment Outcome

HIGHLANDS RANCH   Colorado, July 7, 2021 Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that the Company has unveiled new data from an independent patient survey…

Read More

Post 17

Vivos Therapeutics Founder & Chief Medical Officer Releases New Book Highlighting His Groundbreaking Work

HIGHLANDS RANCH   Colorado, May 26, 2021 HIGHLANDS RANCH, Colo., May 26, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), HIGHLANDS RANCH, Colo., May 26, 2021 – Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered…

Read More

Post 16

Vivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update

Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH Colorado, May 17, 2021 HIGHLANDS RANCH, Colo., May 17, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), HIGHLANDS RANCH, Colo., May 17, 2021 – Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative…

Read More

Post 15

Vivos Therapeutics Schedules First Quarter 2021 Financial Results Conference Call

Call Scheduled for Monday, May 17, 2021 at 5:00 pm ET HIGHLANDS RANCH   Colorado, March 13, 2021 HIGHLANDS RANCH, Colo., March 13, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate…

Read More

Post 14

Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

HIGHLANDS RANCH   Colorado, May 11, 2021 Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its…

Read More